294 related articles for article (PubMed ID: 21980511)
1. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
[TBL] [Abstract][Full Text] [Related]
2. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
3. Germline mutation in the RAD51B gene confers predisposition to breast cancer.
Golmard L; Caux-Moncoutier V; Davy G; Al Ageeli E; Poirot B; Tirapo C; Michaux D; Barbaroux C; d'Enghien CD; Nicolas A; Castéra L; Sastre-Garau X; Stern MH; Houdayer C; Stoppa-Lyonnet D
BMC Cancer; 2013 Oct; 13():484. PubMed ID: 24139550
[TBL] [Abstract][Full Text] [Related]
4. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain).
Sánchez-Bermúdez AI; Sarabia-Meseguer MD; García-Aliaga Á; Marín-Vera M; Macías-Cerrolaza JA; Henaréjos PS; Guardiola-Castillo V; Peña FA; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
Eur J Med Genet; 2018 Jun; 61(6):355-361. PubMed ID: 29409816
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition.
Dos Santos ES; Caputo SM; Castera L; Gendrot M; Briaux A; Breault M; Krieger S; Rogan PK; Mucaki EJ; Burke LJ; ; Bièche I; Houdayer C; Vaur D; Stoppa-Lyonnet D; Brown MA; Lallemand F; Rouleau E
Breast Cancer Res Treat; 2018 Apr; 168(2):311-325. PubMed ID: 29236234
[TBL] [Abstract][Full Text] [Related]
7. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
9. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations in RAD51C in Jewish high cancer risk families.
Kushnir A; Laitman Y; Shimon SP; Berger R; Friedman E
Breast Cancer Res Treat; 2012 Dec; 136(3):869-74. PubMed ID: 23117857
[TBL] [Abstract][Full Text] [Related]
11. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
[TBL] [Abstract][Full Text] [Related]
12. Germline RAD51C mutations in ovarian cancer susceptibility.
Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
[TBL] [Abstract][Full Text] [Related]
13. Retesting of women who are negative for a
Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS
J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482
[TBL] [Abstract][Full Text] [Related]
14. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
15. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
[TBL] [Abstract][Full Text] [Related]
16. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
[TBL] [Abstract][Full Text] [Related]
17. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
18. Mutation screening of RAD51C in high-risk breast and ovarian cancer families.
Lu W; Wang X; Lin H; Lindor NM; Couch FJ
Fam Cancer; 2012 Sep; 11(3):381-5. PubMed ID: 22476429
[TBL] [Abstract][Full Text] [Related]
19. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes.
Brandão RD; Mensaert K; López-Perolio I; Tserpelis D; Xenakis M; Lattimore V; Walker LC; Kvist A; Vega A; Gutiérrez-Enríquez S; Díez O; ; de la Hoya M; Spurdle AB; De Meyer T; Blok MJ
Int J Cancer; 2019 Jul; 145(2):401-414. PubMed ID: 30623411
[TBL] [Abstract][Full Text] [Related]
20. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]